Microbiome influencers of checkpoint blockade–associated toxicity

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Immunotherapy has greatly improved cancer outcomes, yet variability in response and off-target tissue damage can occur with these treatments, including immune checkpoint inhibitors (ICIs). Multiple lines of evidence indicate the host microbiome influences ICI response and risk of immune-related adverse events (irAEs). As the microbiome is modifiable, these advances indicate the potential to manipulate microbiome components to increase ICI success. We discuss microbiome features associated with ICI response, with focus on bacterial taxa and potential immune mechanisms involved in irAEs, and the overall goal of driving novel approaches to manipulate the microbiome to improve ICI efficacy while avoiding irAE risk.

Original languageEnglish (US)
Article numbere20220948
JournalJournal of Experimental Medicine
Volume220
Issue number3
DOIs
StatePublished - Mar 6 2023

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Microbiome influencers of checkpoint blockade–associated toxicity'. Together they form a unique fingerprint.

Cite this